John Heymach

Oct 4, 2024 | nature.com | Junya Fujimoto |Andrew Futreal |John Heymach |Jia Huang Wu |Christopher I. Amos |Jianjun Zhang

AbstractLung Cancer remains the leading cause of cancer deaths in the USA and worldwide. Non-small cell lung cancer (NSCLC) harbors high transcriptomic intratumor heterogeneity (RNA-ITH) that limits the reproducibility of expression-based prognostic models.

Sep 25, 2024 | nature.com | John Heymach

AbstractNon-small-cell lung cancer (NSCLC) is one of the most frequent cancer types and is responsible for the majority of cancer-related deaths worldwide. The management of NSCLC has improved considerably, especially in the past 10 years.

Sep 9, 2024 | onclive.com | John Heymach

CommentaryVideoSeptember 9, 2024Author(s):Fact checked by:John V. Heymach, MD, PhD, discusses updated outcomes from the AEGEAN trial of perioperative durvalumab vs placebo in resectable non–small cell lung cancer. John V.

Aug 20, 2024 | nature.com | John Heymach

Correction to: Nature Medicine https://doi.org/10.1038/s41591-018-0007-9, published online 23 April 2018. In the version of the article initially published, in Supplementary Fig. 7c, the ERK1/2 blot (afatinib treatment) was flipped with respect to the drug concentration. The corrected version is shown below as Fig. 1. The blots shown in Supplementary Fig. 10d were a repeat of the experiment and have now been corrected to show the membranes that correspond to Supplementary Fig. 7c.

Jun 25, 2024 | onclive.com | John Heymach

John Heymach, MD, PhD, professor, chair, David Bruton, Jr Chair in Cancer Research, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses findings from an exploratory subgroup analysis of the phase 3 AEGEAN trial (NCT03800134), which evaluated perioperative durvalumab (Imfinzi) plus neoadjuvant chemotherapy in patients with resectable non–small cell lung cancer (NSCLC) and baseline N2 lymph node...